IGC Expands Phytocan
IGC Expands Phytocannabinoid IP Portfolio with Patent Filing for Method & Composition for Treating Seizure Disorders
June 20, 2016 08:00 ET | India Globalization Capital
BETHESDA, Md., June 20, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE:IGC) announces today that it has filed a patent related to compositions and methods for treating multiple...
IGC Files Internatio
IGC Files International Applications for Cannabinoid Composition and Method Patents
March 15, 2016 08:30 ET | India Globalization Capital
Bethesda, Md, March 15, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (IGC) announces today that it has expanded the scope of its patent strategy to include international patent...
IGC Expands Infrastr
IGC Expands Infrastructure Development Capabilities with Acquisition
February 16, 2016 08:00 ET | India Globalization Capital
Bethesda, MD, Feb. 16, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (IGC) announces today that it has acquired Cabaran Ultima, a 30 year old international project development company...
Patent for Cannabino
Patent for Cannabinoid-based Therapy for Cachexia
September 21, 2015 08:00 ET | India Globalization Capital
Bethesda, Sept. 21, 2015 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (IGC) announces that the company applied for a provisional patent based on a novel therapy that uses cannabinoid extracts...
Upcoming BIO International Conventions to be Held in Life Science's "Big 3" Regions
June 22, 2015 07:00 ET | Big3Bio
SAN FRANCISCO, CA--(Marketwired - June 22, 2015) - Big3Bio is proud to announce that the Biotechnology Industry Organization (BIO), the life science industry's largest trade association, has named the...
Nemus Bioscience Inc. logo
NEMUS to Move Forward With Cannabinoid-Based Therapy for Open-Angle Glaucoma
December 04, 2014 13:05 ET | Nemus Bioscience Inc.
COSTA MESA, Calif., Dec. 4, 2014 (GLOBE NEWSWIRE) -- NEMUS Bioscience, Inc. (OTC:NMUS) reports that data recently presented at the American Association of Pharmaceutical Scientists (AAPS) meeting in...
AIMLogo.jpg
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
July 22, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, July 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print])...
AIMLogo.jpg
Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction
April 08, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and...
Big3Bio, Covering the Life Science News and Breakthroughs From the World's Top 3 Bioclusters, Announces Launch
March 18, 2014 11:41 ET | Big3Bio
SAN FRANCISCO, CA--(Marketwired - March 18, 2014) - BigBio Communications announces the upcoming launch of Big3Bio (www.big3bio.com), the industry's only provider...
AIMLogo.jpg
Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries
March 10, 2014 11:00 ET | AIM ImmunoTech Inc.
PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it and its partner in Latin America, GP Pharm, are planning...